Why the study?
Does triple anti-platelet therapy (aspirin, clopidogrel, and cilostazol) reduce 6-month major adverse cardiovascular and cerebrovascular events compared to dual anti-platelet therapy in patients receiving percutaneous coronary intervention with drug-eluting stents?
Does triple anti-platelet therapy (aspirin, clopidogrel, and cilostazol) reduce 6-month major adverse cardiovascular and cerebrovascular events compared to dual anti-platelet therapy in patients receiving percutaneous coronary intervention with drug-eluting stents?
The CILON-T trial is designed to determine whether adding cilostazol to dual anti-platelet therapy reduces ischemic events and platelet reactivity in real-world patients undergoing PCI with drug-eluting stents.
No takes yet. Share an insight, caveat, or question.
Will inform triple antiplatelet use after DES-PCI; RCT extends evidence on cilostazol for ischemic events and reactivity.
Lee et al. (2010) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: